JP2019536438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536438A5 JP2019536438A5 JP2019518299A JP2019518299A JP2019536438A5 JP 2019536438 A5 JP2019536438 A5 JP 2019536438A5 JP 2019518299 A JP2019518299 A JP 2019518299A JP 2019518299 A JP2019518299 A JP 2019518299A JP 2019536438 A5 JP2019536438 A5 JP 2019536438A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- position corresponding
- fusion protein
- alk4
- actriib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022157844A JP2022177286A (ja) | 2016-10-05 | 2022-09-30 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404727P | 2016-10-05 | 2016-10-05 | |
| US62/404,727 | 2016-10-05 | ||
| US201762510417P | 2017-05-24 | 2017-05-24 | |
| US62/510,417 | 2017-05-24 | ||
| PCT/US2017/055426 WO2018067879A1 (en) | 2016-10-05 | 2017-10-05 | Alk4:actriib heteromultimers and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022157844A Division JP2022177286A (ja) | 2016-10-05 | 2022-09-30 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536438A JP2019536438A (ja) | 2019-12-19 |
| JP2019536438A5 true JP2019536438A5 (cg-RX-API-DMAC7.html) | 2020-11-12 |
| JP7219705B2 JP7219705B2 (ja) | 2023-02-08 |
Family
ID=61831282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518299A Active JP7219705B2 (ja) | 2016-10-05 | 2017-10-05 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| JP2022157844A Pending JP2022177286A (ja) | 2016-10-05 | 2022-09-30 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022157844A Pending JP2022177286A (ja) | 2016-10-05 | 2022-09-30 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10934532B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3522913A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7219705B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190075078A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110678195A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017338921A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019006993A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3039573A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA46472A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201813978A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018067879A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7055636B2 (ja) | 2015-04-06 | 2022-04-18 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| JP6810702B2 (ja) | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| JP7219705B2 (ja) | 2016-10-05 | 2023-02-08 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| EP3522912A4 (en) | 2016-10-05 | 2020-10-14 | Acceleron Pharma Inc. | HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES |
| KR102761094B1 (ko) | 2016-10-05 | 2025-02-03 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| WO2019213446A1 (en) * | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
| CN111269943B (zh) * | 2019-08-10 | 2023-01-06 | 湖南文理学院 | 一种通过基因敲除技术增加斑马鱼生长速度的方法 |
| WO2021119136A1 (en) * | 2019-12-10 | 2021-06-17 | Acceleron Pharma Inc. | Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension |
| KR20220148189A (ko) * | 2020-02-03 | 2022-11-04 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| KR20230002391A (ko) * | 2020-03-13 | 2023-01-05 | 악셀레론 파마 인코포레이티드 | 신장 질환 또는 병태를 치료하기 위한 단일-가지 actriia 및 actriib 이종다량체 및 치료 방법 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| JP2023534127A (ja) * | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
| US20220288226A1 (en) * | 2020-08-27 | 2022-09-15 | Enosi Life Sciences Corp. | Methods and compositions to treat autoimmune diseases and cancer |
| US20240174733A1 (en) * | 2021-03-10 | 2024-05-30 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
| KR20230169123A (ko) * | 2021-03-10 | 2023-12-15 | 악셀레론 파마 인코포레이티드 | Actrii-alk4 길항제 및 심부전을 치료하는 방법 |
| BR112023018283A2 (pt) * | 2021-03-10 | 2023-10-31 | Acceleron Pharma Inc | Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca |
| EP4444747A1 (en) * | 2021-12-10 | 2024-10-16 | Biogen MA Inc. | Modified actriib proteins and methods of use thereof |
| WO2024238950A1 (en) * | 2023-05-18 | 2024-11-21 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii variants |
| WO2025183964A1 (en) * | 2024-02-27 | 2025-09-04 | Alivegen Usa, Inc | Methods of treating myostatin-related or activin a-related disorders using novel hybrid actriib ligand trap proteins |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ATE234920T1 (de) | 1992-11-17 | 2003-04-15 | Ludwig Inst Cancer Res | Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen |
| US7592428B1 (en) | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| DE60027135T2 (de) | 1999-01-21 | 2007-01-11 | Metamorphix, Inc. | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US7820620B2 (en) | 2003-09-15 | 2010-10-26 | Research Development Foundation | Cripto antagonism of activin and TGF-b signaling |
| EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| US7612041B2 (en) | 2005-11-23 | 2009-11-03 | Acceleron Pharma Inc. | Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| JP2010512326A (ja) | 2006-12-08 | 2010-04-22 | アクセルロン ファーマ， インコーポレイテッド | Ｃｅｒｂｅｒｕｓ、Ｃｏｃｏおよびこれらの誘導体の使用 |
| US20100035918A1 (en) | 2007-01-30 | 2010-02-11 | Biogen Idec Ma Inc | Imidazolone Compounds and Methods of Making and Using the Same |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| EP2140005B1 (en) | 2007-03-19 | 2013-12-11 | National Research Council of Canada | Fusion proteins comprising two tgf-beta binding domains |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| US8058229B2 (en) | 2008-08-14 | 2011-11-15 | Acceleron Pharma Inc. | Method of increasing red blood cell levels or treating anemia in a patient |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP2326670A4 (en) | 2008-09-17 | 2014-04-16 | Nat Res Council Canada | HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY |
| MY159483A (en) | 2008-11-26 | 2017-01-13 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| AU2010296018B2 (en) | 2009-09-16 | 2016-05-05 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| FR2951408B1 (fr) | 2009-10-15 | 2012-01-13 | Renault Sa | Cadre moteur pour moteur electrique de vehicule automobile |
| CN103221426B (zh) | 2010-08-16 | 2016-01-13 | 安姆根公司 | 结合肌肉生长抑制素的抗体、组合物和方法 |
| UY33827A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| WO2013055809A1 (en) * | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
| US10851178B2 (en) * | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| EP2831105B1 (en) | 2012-03-28 | 2017-08-09 | The Board of Regents of The University of Texas System | Tgf type ii-type iii receptor fusions |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| WO2016090035A2 (en) | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| JP2018510637A (ja) | 2015-03-26 | 2018-04-19 | アクセルロン ファーマ， インコーポレイテッド | フォリスタチン関連融合タンパク質およびその使用 |
| JP7055636B2 (ja) | 2015-04-06 | 2022-04-18 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| JP6810702B2 (ja) | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| SMT202100294T1 (it) | 2015-04-22 | 2021-07-12 | Biogen Ma Inc | Proteine trappola del liganto acriib ibride innovative per il trattamento di patologie da deperimento muscolare |
| WO2016205370A1 (en) | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
| CA2996996A1 (en) | 2015-08-31 | 2017-03-09 | National Research Council Of Canada | Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof |
| KR20180128405A (ko) * | 2016-02-22 | 2018-12-03 | 악셀레론 파마 인코포레이티드 | 면역 활성 증가에 사용하기 위한 ActRII 길항제 |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| EP3481860A4 (en) | 2016-07-07 | 2020-01-22 | Acceleron Pharma Inc. | HETEROMULTIMERS OF THE TGF-BETA SUPER FAMILY AND USES THEREOF |
| WO2018009732A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| JP7219705B2 (ja) | 2016-10-05 | 2023-02-08 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
-
2017
- 2017-10-05 JP JP2019518299A patent/JP7219705B2/ja active Active
- 2017-10-05 TW TW106134359A patent/TW201813978A/zh unknown
- 2017-10-05 BR BR112019006993A patent/BR112019006993A2/pt not_active IP Right Cessation
- 2017-10-05 WO PCT/US2017/055426 patent/WO2018067879A1/en not_active Ceased
- 2017-10-05 CN CN201780075170.8A patent/CN110678195A/zh active Pending
- 2017-10-05 EP EP17859224.2A patent/EP3522913A4/en active Pending
- 2017-10-05 MA MA046472A patent/MA46472A/fr unknown
- 2017-10-05 AU AU2017338921A patent/AU2017338921A1/en not_active Abandoned
- 2017-10-05 KR KR1020197012900A patent/KR20190075078A/ko not_active Ceased
- 2017-10-05 CA CA3039573A patent/CA3039573A1/en active Pending
- 2017-10-05 US US15/726,255 patent/US10934532B2/en active Active
-
2020
- 2020-12-28 US US17/134,703 patent/US12054753B2/en active Active
-
2022
- 2022-09-30 JP JP2022157844A patent/JP2022177286A/ja active Pending
-
2024
- 2024-06-20 US US18/749,233 patent/US20250084388A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536438A5 (cg-RX-API-DMAC7.html) | ||
| JP7101732B2 (ja) | 抗ａｌｋ２抗体 | |
| JP2018516240A5 (cg-RX-API-DMAC7.html) | ||
| JP2025004103A5 (cg-RX-API-DMAC7.html) | ||
| EP2447281B1 (en) | Novel anti-PLGF antibody | |
| CA2496795C (en) | Compositions and methods for treating cardiovascular disease | |
| JP2022093640A (ja) | 抗ｉｌ－１治療に関する新しい適応症 | |
| JP2019529509A5 (cg-RX-API-DMAC7.html) | ||
| TW201813978A (zh) | ＡＬＫ４：ＡｃｔＲＩＩＢ異多聚體及其用途 | |
| JP2014518064A5 (cg-RX-API-DMAC7.html) | ||
| JP2011520793A5 (cg-RX-API-DMAC7.html) | ||
| KR20190071758A (ko) | 신규한 하이브리드 actriib 리간드 트랩 단백질을 사용한 근육 소모 및 골 질환의 치료 방법 | |
| JP2008106076A (ja) | ＩＩ型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 | |
| JP2007500132A (ja) | Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法 | |
| JP2010508816A5 (cg-RX-API-DMAC7.html) | ||
| WO2013023557A1 (zh) | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 | |
| WO2010019263A2 (en) | Soluble flt constructs for treating cancers | |
| KR20200026789A (ko) | 시누클레인병증을 치료하기 위한 조성물 및 방법 | |
| JP2014513941A (ja) | ＦＧＦＲ−Ｆｃ融合蛋白質およびその使用 | |
| EP3169348B1 (en) | Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases | |
| US20200148736A1 (en) | GM-CSF Variants and Methods of Use | |
| JP2025516361A (ja) | Ｇｌｐ－１と、免疫グロブリンｆｃと、ｉｇｆ－１とを含む融合タンパク質並びにその用途 | |
| TW202334208A (zh) | 用於治療癌症的組合療法 | |
| WO2022256820A1 (en) | Multispecific antagonists | |
| KR20230111192A (ko) | 액티빈 및 종양괴사인자-알파의 이작용성 길항제 및 이의 용도 |